Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study

Sloan W Rush,1,2 Jennifer Chain,3 Hiranmoy Das2 1Panhandle Eye Group, Amarillo, TX, 79106, USA; 2Texas Tech University Health Sciences Center, Amarillo, TX, 79106, USA; 3Oklahoma Blood Institute, Oklahoma City, OK, 73104, USACorrespondence: Sloan W RushPanhandle Eye Group, 7400 Fleming Ave, Amarillo...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rush SW, Chain J, Das H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	dry eye disease corneal epithelial stem cells conjunctival goblet cells supernatant chronic ocular surface disease glycocalyx galectin-3 mucins stem cells corneal epithelium tear film keratoconjunctivitis sicca Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/075492f8e91e44e2ae76f62e66d857bb
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:075492f8e91e44e2ae76f62e66d857bb
record_format	dspace
spelling	oai:doaj.org-article:075492f8e91e44e2ae76f62e66d857bb2021-12-02T16:50:11ZCorneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study1177-5483https://doaj.org/article/075492f8e91e44e2ae76f62e66d857bb2021-07-01T00:00:00Zhttps://www.dovepress.com/corneal-epithelial-stem-cell-supernatant-in-the-treatment-of-severe-dr-peer-reviewed-fulltext-article-OPTHhttps://doaj.org/toc/1177-5483Sloan W Rush,1,2 Jennifer Chain,3 Hiranmoy Das2 1Panhandle Eye Group, Amarillo, TX, 79106, USA; 2Texas Tech University Health Sciences Center, Amarillo, TX, 79106, USA; 3Oklahoma Blood Institute, Oklahoma City, OK, 73104, USACorrespondence: Sloan W RushPanhandle Eye Group, 7400 Fleming Ave, Amarillo, TX, 79106, USATel +1 806 353-0125Email sloan.rush@paneye.comPurpose: To report the subjective assessment of topical self-administered, cadaver-derived corneal epithelial stem cell supernatant for treatment of severe dry eye disease (DED).Methods: Thirty-four eyes of 17 patients with advanced DED as defined by Standardized Patient Evaluation of Eye Dryness (SPEEDTM) questionnaire ≥ 14, Ocular Surface Disease Index (OSDI©) score ≥ 40 and documented attempt of at least six conventional dry eye therapies were enrolled into a prospective clinical trial at a single private practice institution. Treatment consisted of patient self-administered topical instillation of the corneal epithelial stem cell-derived product four times daily in both eyes for 12 weeks. Patient-reported outcome measures (PROMs) were taken with the SPEEDTM questionnaire (the main outcome variable), OSDI© score and visual analog score (VAS; UNC Dry Eye Management Scale©), and objective clinical measurements were taken with best-corrected visual acuity (BCVA), corneal topographic index measurements and tear film osmolarity. These measurements were compared at baseline versus the endpoint at completion of the 12-week treatment.Results: All 34 eyes tolerated the treatment without any adverse events or significant side effects. Compared with baseline, both the SPEEDTM questionnaire and the VAS significantly improved at the conclusion of the 12-week treatment (p = 0.0054 and p = 0.0202, respectively). The OSDI© improved by an average of 10.9 points after the treatment but was not statistically significant (p = 0.1409). There were no significant changes in any of the objective clinical measurements. None of the study subjects failed to complete the treatment course, experienced decrease in any of the PROMs or lost one or more lines of BCVA during the follow-up period.Conclusion: Topical corneal epithelial stem cell-derived supernatant that can be self-administered by the patient shows promise at improving patient symptoms and quality of life in the setting of severe DED that is unresponsive to conventional therapies.Keywords: dry eye disease, corneal epithelial stem cells, conjunctival goblet cells, supernatant, chronic ocular surface disease, glycocalyx, galectin-3, mucinsRush SWChain JDas HDove Medical Pressarticledry eye diseasecorneal epithelial stem cellsconjunctival goblet cellssupernatantchronic ocular surface diseaseglycocalyxgalectin-3mucinsstem cellscorneal epitheliumtear filmkeratoconjunctivitis siccaOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 15, Pp 3097-3107 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	dry eye disease corneal epithelial stem cells conjunctival goblet cells supernatant chronic ocular surface disease glycocalyx galectin-3 mucins stem cells corneal epithelium tear film keratoconjunctivitis sicca Ophthalmology RE1-994
spellingShingle	dry eye disease corneal epithelial stem cells conjunctival goblet cells supernatant chronic ocular surface disease glycocalyx galectin-3 mucins stem cells corneal epithelium tear film keratoconjunctivitis sicca Ophthalmology RE1-994 Rush SW Chain J Das H Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study
description	Sloan W Rush,1,2 Jennifer Chain,3 Hiranmoy Das2 1Panhandle Eye Group, Amarillo, TX, 79106, USA; 2Texas Tech University Health Sciences Center, Amarillo, TX, 79106, USA; 3Oklahoma Blood Institute, Oklahoma City, OK, 73104, USACorrespondence: Sloan W RushPanhandle Eye Group, 7400 Fleming Ave, Amarillo, TX, 79106, USATel +1 806 353-0125Email sloan.rush@paneye.comPurpose: To report the subjective assessment of topical self-administered, cadaver-derived corneal epithelial stem cell supernatant for treatment of severe dry eye disease (DED).Methods: Thirty-four eyes of 17 patients with advanced DED as defined by Standardized Patient Evaluation of Eye Dryness (SPEEDTM) questionnaire ≥ 14, Ocular Surface Disease Index (OSDI©) score ≥ 40 and documented attempt of at least six conventional dry eye therapies were enrolled into a prospective clinical trial at a single private practice institution. Treatment consisted of patient self-administered topical instillation of the corneal epithelial stem cell-derived product four times daily in both eyes for 12 weeks. Patient-reported outcome measures (PROMs) were taken with the SPEEDTM questionnaire (the main outcome variable), OSDI© score and visual analog score (VAS; UNC Dry Eye Management Scale©), and objective clinical measurements were taken with best-corrected visual acuity (BCVA), corneal topographic index measurements and tear film osmolarity. These measurements were compared at baseline versus the endpoint at completion of the 12-week treatment.Results: All 34 eyes tolerated the treatment without any adverse events or significant side effects. Compared with baseline, both the SPEEDTM questionnaire and the VAS significantly improved at the conclusion of the 12-week treatment (p = 0.0054 and p = 0.0202, respectively). The OSDI© improved by an average of 10.9 points after the treatment but was not statistically significant (p = 0.1409). There were no significant changes in any of the objective clinical measurements. None of the study subjects failed to complete the treatment course, experienced decrease in any of the PROMs or lost one or more lines of BCVA during the follow-up period.Conclusion: Topical corneal epithelial stem cell-derived supernatant that can be self-administered by the patient shows promise at improving patient symptoms and quality of life in the setting of severe DED that is unresponsive to conventional therapies.Keywords: dry eye disease, corneal epithelial stem cells, conjunctival goblet cells, supernatant, chronic ocular surface disease, glycocalyx, galectin-3, mucins
format	article
author	Rush SW Chain J Das H
author_facet	Rush SW Chain J Das H
author_sort	Rush SW
title	Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study
title_short	Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study
title_full	Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study
title_fullStr	Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study
title_full_unstemmed	Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study
title_sort	corneal epithelial stem cell supernatant in the treatment of severe dry eye disease: a pilot study
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/075492f8e91e44e2ae76f62e66d857bb
work_keys_str_mv	AT rushsw cornealepithelialstemcellsupernatantinthetreatmentofseveredryeyediseaseapilotstudy AT chainj cornealepithelialstemcellsupernatantinthetreatmentofseveredryeyediseaseapilotstudy AT dash cornealepithelialstemcellsupernatantinthetreatmentofseveredryeyediseaseapilotstudy
_version_	1718383078871662592

Corneal Epithelial Stem Cell Supernatant in the Treatment of Severe Dry Eye Disease: A Pilot Study

Ejemplares similares